THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM;THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY;YALE UNIVERSITY
发明人:
Chandrashekhar PASARE,Scott N. FURLAN,Noah W. PALM,Arun UNNI
申请号：
US15034113
公开号：
US20170007685A1
申请日:
2014.11.05
申请国别(地区):
US
年份:
2017
代理人:
摘要：
A lymphoma cell line was engineered to express surface IgG1 Fc. These tumor cells were taken up rapidly by DCs, leading to enhanced cross-presentation of tumor-derived antigen to CD8 T cells. IgG1-Fc tumors failed to grow in vivo and prophylactic vaccination in an animal model resulted in rejection of unmanipulated tumor cells. Furthermore, IgG1-Fc tumor cells were able to slow the growth of an unmanipulated primary tumor when used as a therapeutic tumor vaccine. This demonstrates that engagement of Fc receptors by tumors expressing the Fc region of IgG1 can induce efficient and protective anti-tumor CD8+ T cell responses without prior knowledge of tumor-specific antigen.
